Victoria Socha

DocwireNews

Interim results from the KidneyIntelX&trade; expanded validation study have been announced in a press release from Renalytix AI. The KidneyIntelX artificial intelligence-enabled in vitro diagnostic uses a machine learning algorithm to examine results from proprietary blood biomarkers in combination with information from a patient&rsquo;s electronic health record (EHR) to generate a rapid kidney function decline (RKFD) score. RKFD is defined as a change in kidney function (glomerular filtration rate) of at least 5 mL/min/1.73 m2 per year.The expanded validation study includes stored patient plasma samples and corresponding EHRs from three academic medical centers: Emory University, the Ichan School of Medicine at Mount Sinai, and the University of Pennsylvania.In the multi-center cohort of patients with type 2 diabetes, performance targets were met or exceeded by the KidneyIntelX algorithm. The algorithm identifies patients experiencing rapid decline in kidney function as well as patients who will progress to kidney failure and/or dialysis. The data will support the ongoing regulatory progress with the US Food and Drug Administration under Breakthrough Device designation, announced in May 2019.Initial performance targets reported in April demonstrated that the ability to predict which patients went on to experience RKFD was significantly increased with the KidneyIntelX machine learning algorithm compared with currently used diagnostic methods. In the expanded validation study population, the positive predictive value of KidneyIntelX for RKFD in patients with type 2 diabetes exceeded 50% in patients who were in the highest 15% of the risk distribution, as well as a negative predictive value of &gt;95% for patients unlikely to develop RKFD.

Jordana Jampel

FDA Approves Novel Blood Test for Alzheimer’s Detection

Dementia

Andrew Moreno

Is Plasma Mannose-Binding Lectin a Clue to Higher VTE Risk?

Katie Kosko

EMBER-3: Imlunestrant Plus Abemaciclib Improves PFS in ER+ Breast Cancer

HR Breast Cancer

Latest News

Positive Results from AI-enabled Validation Study

Nephrology Times

Interim results from the KidneyIntelX™ expanded validation study have been announced in a press release from Renalytix AI. 

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe